We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




MRI Analysis Tools Provide Insights into how Tumors Respond to Radiotherapy

By MedImaging staff writers
Posted on 29 May 2008
New magnetic resonance imaging (MRI) image analysis tools are being used to glean important information about the way tumors respond to radiation therapy. More...
This may ultimately affect the planning of patient treatment following radiation therapy as this research can now be carried over into human studies.

VirtualScopics, Inc. (Rochester, NY, USA), a developer of advanced medical imaging for clinical trials, announced that its chief scientific officer, Dr. Edward Ashton, Ph.D. had two speaking engagements and co-authored an abstract at the International Society for Magnetic Resonance Imaging in Medicine (ISMRM) conference in Toronto, Canada. Dr. Ashton's presentations on May 7 and 8, 2008, focused on the company's work in dynamic contrast enhanced MRI, a sophisticated medical image analysis technique that measures blood flow and permeability and enables the early detection of a drug's effectiveness in treating cancer and other diseases.

"Our proprietary analysis techniques surrounding the measuring of blood flow within a tumor continue to demonstrate great value to the industry,” stated Dr. Ashton. He further added, "Because of the improved specificity and sensitivity of our tools we were able to determine that our method, compared to three other methods, was the only one that detected the treatment effect of our customer's compound. Our presentations at this year's ISMRM conference [were] made in conjunction with leaders in the pharmaceutical industry to highlight the impacts our analysis tools have made in providing them with quicker and more reliable information to evaluate the efficacy of their drugs.”

Dr. Ashton also presented data related to treating naturally occurring solid tumors in canines. In both human and animal health studies VirtualScopics is able to provide drug makers with more information sooner, enabling them to make earlier decisions on either suspending ineffective drug trials or moving effective drugs forward in the expensive clinical trial process, saving drug makers significant time and money.

VirtualScopics is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a software platform for analysis and modeling of both structural and functional medical images.


Related Links:
VirtualScopics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.